Fifty 1 Labs and UAV Corp Announce AI-Driven Strategy for $50 Million Valuation and NASDAQ Uplisting

Fifty 1 Labs, Inc. (OTC: FITY) and UAV Corp (OTC: UMAV) have embarked on a strategic initiative centered around artificial intelligence (AI) with the goal of elevating Fifty 1 Labs to a $50 million valuation and securing an uplisting to the NASDAQ Capital Market. This Nevada-based entity, known for its expertise in AI-driven drug repurposing and functional medicine, has detailed a 'Game Plan' that encompasses a $1 million research and development (R&D) project, the introduction of a digital platform by July 2025, and the acquisition of strategic biotech firms. The strategy is bolstered by a $350,000 investment from insiders and the deferral of leadership salaries, highlighting the team's dedication to these objectives.

The company's approach is designed to innovate within the $320.6 billion functional medicine sector by broadening its offerings to include personalized healthcare solutions powered by AI. With a leadership roster featuring Nobel laureate Dr. James Orbinski and former NFL player Brandon Spikes, Fifty 1 Labs is carving out a niche at the crossroads of biotechnology and wellness. The envisioned digital platform and biotech acquisitions are pivotal to this plan, aimed at speeding up the identification of repurposed treatments and strengthening the company's standing in the market.

At the heart of this ambitious endeavor is Fifty1 AI Labs LLC, a subsidiary of Fifty 1 Labs, which is spearheading the R&D efforts with the aim of uncovering new treatments by May 2026. Additionally, the company has scheduled a shareholder event for the third quarter of 2025 to further involve its investors in its growth journey. This strategic roadmap not only showcases Fifty 1 Labs' pioneering methods in healthcare but also its capacity to influence the biotech and wellness sectors significantly. For more information, visit https://www.fifty1labs.com.